The psychomotor and cognitive effects of a new antihistamine, mizolastine, compared to terfenadine, triprolidine and placebo in healthy volunteers.
Eighteen healthy volunteers received mizolastine 5 mg, 15 mg or 45 mg, terfenadine 60 mg, triprolidine 10 mg or placebo in a 6-way crossover, double blind study. Following each dose, subjects performed a series of tests of cognitive function and psychomotor performance at 1, 3, 5, 8 and 24 hours post-dose. The test battery included critical flicker fusion, choice reaction time, tracking, Stroop and Sternberg memory tests and assessment of subjective sedation. Sedative effects and a concomitant reduction in psychomotor and cognitive function were observed following triprolidine, terfenadine and the highest dose of mizolastine, 45 mg, e.g. triprolidine reduced CFF threshold by 1.5 Hz and increased reaction time by 50 ms, impairments comparable to those caused by blood alcohol concentrations of 50 mg%, the legal limit in many countries. Mizolastine 5 mg did not differ significantly from placebo and at 15 mg differed only at one test point at one time. It may be concluded that mizolastine (5 mg and 15 mg) is free from disruptive effects on cognitive function and psychomotor performance, in contrast to terfenadine 60 mg, triprolidine 10 mg and mizolastine 45 mg.
Kerr
J S
JS
Human Psychopharmacology Research Unit, University of Surrey, Milford Hospital, Godalming, UK.
Dunmore
C
C
Hindmarch
I
I
D000293:Adolescent; D000328:Adult; D001562:Benzimidazoles / Q000494:pharmacology*; D003071:Cognition / Q000187:drug effects*; D006634:Histamine H1 Antagonists; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects; D010919:Placebos; D011597:Psychomotor Performance / Q000187:drug effects*; D016593:Terfenadine / Q000494:pharmacology*; D014311:Triprolidine / Q000494:pharmacology*
D001562:Benzimidazoles; D006634:Histamine H1 Antagonists; D010919:Placebos; C076170:mizolastine; D014311:Triprolidine; D016593:Terfenadine